-
Article
Open AccessPan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a mult...
-
Article
Open AccessCase series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
Though advanced cancers generally display complex molecular portfolios, there is a subset of patients whose malignancies possess only one genomic alteration or alterations in one oncogenic pathway. We assess h...
-
Article
Open AccessReal-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting the molecular findings and accessing drugs/clinical trials is challenging. Furthermore, many tumors show resistance to ...
-
Article
Open AccessMultivariate analysis of prognostic factors in patients with pulmonary actinomycosis
There have been few studies of pulmonary actinomycosis, which is an uncommon anaerobic infection. Consequently, the optimal therapeutic regimen, appropriate duration of treatment, long-term prognosis, and fact...
